PMID- 20827268
OWN - NLM
STAT- MEDLINE
DCOM- 20101020
LR  - 20131121
IS  - 1532-6535 (Electronic)
IS  - 0009-9236 (Linking)
VI  - 88
IP  - 4
DP  - 2010 Oct
TI  - Elevated levels of asymmetric dimethylarginine in chronic heart failure: a 
      pathophysiologic link between oxygen radical load and impaired vasodilator 
      capacity and the therapeutic effect of allopurinol.
PG  - 506-12
LID - 10.1038/clpt.2010.116 [doi]
AB  - Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric 
      oxide-dependent vasodilation. In 113 patients with chronic heart failure (CHF) 
      and 26 controls, ADMA level was studied in relation to peripheral blood flow and 
      vasodilator capacity. Further, the effects of allopurinol on concentrations of 
      reactive oxygen species (ROS) and ADMA and peripheral vasodilator capacity were 
      tested in a double-blind design. ADMA level was found to be elevated in CHF 
      patients as compared with controls and increased in parallel with New York Heart 
      Association (NYHA) class and exercise capacity (all P < 0.0001). The level of 
      ADMA predicted resting blood flow (P < 0.05) and postischemic vasodilator 
      capacity (P < 0.001). Sixty eight patients died during the follow-up period. The 
      level of ADMA predicted survival after multivariable adjustment (P = 0.04). 
      Allopurinol reduced uric acid (UA) concentration (P < 0.001) and decreased ROS 
      concentration (allantoin, P < 0.01). Allopurinol lowered ADMA concentration (P = 
      0.02); postischemic vasodilation as well as endothelium-dependent vasodilation 
      (both P < 0.05) improved. ADMA may be a pathophysiologic factor that is modulated 
      by ROS accumulation and contributes to impaired vascular regulation in CHF.
FAU - von Haehling, S
AU  - von Haehling S
AD  - Applied Cachexia Research, Department of Cardiology, Charite Medical School, 
      Campus Virchow-Klinikum, Berlin, Germany.
FAU - Bode-Boger, S M
AU  - Bode-Boger SM
FAU - Martens-Lobenhoffer, J
AU  - Martens-Lobenhoffer J
FAU - Rauchhaus, M
AU  - Rauchhaus M
FAU - Schefold, J C
AU  - Schefold JC
FAU - Genth-Zotz, S
AU  - Genth-Zotz S
FAU - Karhausen, T
AU  - Karhausen T
FAU - Cicoira, M
AU  - Cicoira M
FAU - Anker, S D
AU  - Anker SD
FAU - Doehner, W
AU  - Doehner W
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20100908
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Free Radical Scavengers)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (dimethylarginine)
RN  - 268B43MJ25 (Uric Acid)
RN  - 29VT07BGDA (Citrulline)
RN  - 63CZ7GJN5I (Allopurinol)
RN  - 94ZLA3W45F (Arginine)
SB  - IM
MH  - Aged
MH  - Allopurinol/*pharmacology/therapeutic use
MH  - Arginine/*analogs & derivatives/blood
MH  - Chronic Disease
MH  - Citrulline/blood
MH  - Cross-Sectional Studies
MH  - Double-Blind Method
MH  - Female
MH  - Free Radical Scavengers/*pharmacology/therapeutic use
MH  - Heart Failure/blood/*physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Reactive Oxygen Species/*metabolism
MH  - Uric Acid/blood
MH  - Vasodilation
EDAT- 2010/09/10 06:00
MHDA- 2010/10/21 06:00
CRDT- 2010/09/10 06:00
PHST- 2010/09/10 06:00 [entrez]
PHST- 2010/09/10 06:00 [pubmed]
PHST- 2010/10/21 06:00 [medline]
AID - clpt2010116 [pii]
AID - 10.1038/clpt.2010.116 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2010 Oct;88(4):506-12. doi: 10.1038/clpt.2010.116. Epub 2010 
      Sep 8.